Trial reportVeterinary research2013
Foot-and-mouth disease virus-like particles produced by a SUMO fusion protein system in Escherichia coli induce potent protective immune responses in guinea pigs, swine and cattle.
Trial report in Veterinary research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 112 citations in OpenAlex.
- Development of a conformation-specific nanobody-based ELISA for quantitative detection of intact Senecavirus A virions and virus-like particles.The Journal of veterinary medical science · 2026Article
- Foot-and-mouth disease virus-like particle mRNA vaccine induces strong humoral and cellular immunity.Applied microbiology and biotechnology · 2026Article
- Optimization of untranslated regions enhances antigen expression and immunogenicity of FMDV P12A3C mRNA vaccine.Virology journal · 2026Article
- Foot-and-Mouth Disease Virus Persistence Divergence Within Serotypes and Vaccine Doses in Vaccinated Cattle.Transboundary and emerging diseases · 2026Article
- Evolutionary and structural insights into VP1 epitopes of representative SAT-type FMDV strains: implications for candidate vaccine selection.Veterinary research · 2025Review
- Development and immunogenicity of adenoviral Fc-fused FMDV virus-like particle vaccine in swine.The veterinary quarterly · 2025Article
- Glycosylated Foot-And-Mouth Disease Virus-Like Particles Produced in Pichia Pastoris Enhance Stability and Immunogenicity.Microbial biotechnology · 2025Article
- Virus-like particle-based liquid phase blocking ELISA for evaluating the efficacy of O-type foot-and-mouth disease vaccines.Applied microbiology and biotechnology · 2025Article
- An integrated structural and immunoinformatic approach to design a multi-epitope based vaccine against the foot-and-mouth disease virus.Scientific reports · 2025Article
- N-terminal truncation of the foot-and-mouth disease virus VP0 protein promotes soluble co-expression and particle assembly stability of viral capsid proteins in Escherichia coli.BMC biotechnology · 2025Article
- Foot-and-Mouth Disease Virus-like Particles Produced inVeterinary sciences · 2025Article
- Astragalus Polysaccharide Nanoemulsion: A Promising Adjuvant for Foot-And-Mouth Disease Virus-Like Particle Vaccines.Transboundary and emerging diseases · 2025Article
- Enhanced Immunogenicity of Foot-and-Mouth Disease Virus-like Particles Using a Water-in-Oil-in-Water Adjuvant.Vaccines · 2024Article
- Review
- A comprehensive and single-use foot-and-mouth disease sero-surveillance prototype employing rationally designed multiple viral antigens.Scientific reports · 2024Article
- Use of virus-like particles and nanoparticle-based vaccines for combating picornavirus infections.Veterinary research · 2024Review
- Evaluation of vaccine efficacy with 2B/T epitope conjugated porcine IgG-Fc recombinants against foot-and-mouth disease virus.The Journal of veterinary medical science · 2024Article
- Review
- Self-Assembling E2-Based Nanoparticles Improve Vaccine Thermostability and Protective Immunity against CSFV.International journal of molecular sciences · 2024Article
- Self-Assembling Nanovaccine Fused with Flagellin Enhances Protective Effect against Foot-and-Mouth Disease Virus.Vaccines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Foot-and-mouth disease virus (FMDV) causes a highly contagious infection in cloven-hoofed animals. The format of FMD virus-like particles (VLP) as a non-replicating particulate vaccine candidate is a promising alternative to conventional inactivated FMDV vaccines. In this study, we explored a prokaryotic system to express and assemble the FMD VLP and validated the potential of VLP as an FMDV vaccine candidate. VLP composed entirely of FMDV (Asia1/Jiangsu/China/2005) capsid proteins (VP0, VP1 and VP3) were simultaneously produced as SUMO fusion proteins by an improved SUMO fusion protein system in E. coli. Proteolytic removal of the SUMO moiety from the fusion proteins resulted in the assembly of VLP with size and shape resembling the authentic FMDV. Immunization of guinea pigs, swine and cattle with FMD VLP by intramuscular inoculation stimulated the FMDV-specific antibody response, neutralizing antibody response, T-cell proliferation response and secretion of cytokine IFN-γ. In addition, immunization with one dose of the VLP resulted in complete protection of these animals from homologous FMDV challenge. The 50% protection dose (PD50) of FMD VLP in cattle is up to 6.34. These results suggest that FMD VLP expressed in E. coli are an effective vaccine in guinea pigs, swine and cattle and support further development of these VLP as a vaccine candidate for protection against FMDV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.